1 |
Siegel D and Ross D (2000) Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radical Bio Med 29, 246-253
DOI
|
2 |
Asher G, Bercovich Z, Tsvetkov P et al (2005) 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell 17, 645-655
DOI
|
3 |
Itoh K, Chiba T, Takahashi S et al (1997) An Nrf2:small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236, 313-322
DOI
|
4 |
Li Y and Jaiswal AK (1994) Human antioxidant response element mediated regulation of type 1 NAD(P)H: quinone oxidoreductase gene expression. Eur J Biochem 226, 31-39
DOI
|
5 |
Vasiliou V, Theurer MJ, Puga A et al (1994) Mouse dioxin-inducible NAD(P)H: menadione oxidoreductase: NMO1 cDNA sequence and genetic differences in mRNA levels. Pharmacogenetics 4, 341-348
DOI
|
6 |
Robertson JA, Chen H and Nebert DW (1986) NAD(P)H: menadione oxidoreductase. Novel purification of enzyme, cDNA and complete amino acid sequence and gene regulation. J Biol Chem 261, 15794-15799
|
7 |
Wasserman WW and Fahl WE (1997) Functional antioxidant responsive elements. Proc Natl Acad Sci U S A 94, 5361-5366
DOI
|
8 |
Li Y, Paonessa JD and Zhang Y (2012) Mechanism of chemical activation of Nrf2. PLoS One 7, e35122
DOI
|
9 |
Landers JP and Bunce NJ (1991) The Ah receptor and the mechanism of dioxin toxicity. Biochem J 276, 273-287
DOI
|
10 |
Kumaki K, Jensen NM, Shire JGM et al (1977) Genetic differences in induction of cytosol reduced-NAD(P): menadione oxidoreductase and microsomal aryl hydrocarbon hydroxylase in the mouse. J Biol Chem 252, 157-165
|
11 |
Radjendirane V and Jaiswal (1999) Antioxidant response element-mediated 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induction of human NAD(P)H:quinone oxidoreductase 1 gene expression. Biochem Pharmacol 58, 1649-1655
DOI
|
12 |
Sporn MB (1996) The war on cancer. Lancet 347, 1377-1381
DOI
|
13 |
Rothman N, Smith MT, Hayes RB et al (1997) Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C → T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 57, 2839-2842
|
14 |
Kensler TW (1997) Chemoprevention by inducers of carcinogen detoxication enzymes. Environ. Health Perspect 105, 965-970
DOI
|
15 |
Fahey JW, Talalay P (1999) Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 37, 973-979
DOI
|
16 |
Siegel D, Anwar A, Winski SL et al (2001) Rapid polyubiquitination and proteasomal degradation of a mutant from of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 59, 263-268
DOI
|
17 |
Malkinson AM, Siegel D, Forrest DL et al (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res 52, 4752-4757
|
18 |
Siegel D and Ross D (2000) Immunodetection ofNAD(P): quinone oxidoreductase 1 (NQO1) in human tissues. Free Rad Biol Med 29, 246-253
DOI
|
19 |
Cancer Genome Atlas Research Network (TCGA) (2012) Comprehensive genomic characterization define human colon and rectal cancer. Nature 487, 330-337
DOI
|
20 |
Siegel D, Yan C and Ross D (2012) NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 83, 1033-1040
DOI
|
21 |
Begleiter A, Robotham E and Leith MK (1992) Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia. Mol Pharmacol 41, 677-682
|
22 |
Li LH, Clark TD, Cowie CH et al (1977) Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of Rauscher leukemia virus. Cancer Treat Rep 61, 815-824
|
23 |
Dong GZ, Youn H, Park MT et al (2009) Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilization of NQO1 protein. Int J Hypethermia 25, 477-487
DOI
|
24 |
Park MT, Song MJ, Lee H et al (2011) β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis activation in cancer cells. PLoS One 6, e25976
DOI
|
25 |
Boveris A, Docampo R, Turrens JF et al (1978) Effect of beta-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi. Biochem J 175, 431-439
DOI
|
26 |
Guo W, Reigan P, Siegel D et al (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:-quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65, 10006-10015
DOI
|
27 |
Khong HT, Dreisbach L, Kindler HL et al (2007) A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naïve, unresectable pancre atic adenocarcinoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25, 15017
|
28 |
Blanco E, Bey EA, Dong Y et al (2007) Beta-lapachonecontaining PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release 122, 365-374
DOI
|
29 |
Dong Y, Chin SF, Blanco E et al (2009) Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 15, 131-139
DOI
|
30 |
Park C, Youn H, Kim H et al (2009) Cyclodextrin-covered gold nanoparticles for targeted delivery of an anti-cancer drug. J Mater Chem 19, 2310-2315
DOI
|
31 |
Schlager JJ and Powis G (1990) Cytosilic NAD(P)H: (quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alchol. Int J Cancer 45, 403-409
DOI
|
32 |
Terai K, Dong GZ, Oh ET et al (2009) Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1. Anticancer Drugs 20, 901-909
DOI
|
33 |
Nioi P and Hayes JD (2004) Contribution of NAD(P)H: quinoneoxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 555, 149-171
DOI
|
34 |
Kaspar JW and Jaiswal AK (2010) Antioxidant-induced phosphorylation of tyrosine 486 leads to rapid nuclear export of Bach 1 that allows Nrf2 to bind to the antitoxidant response element and activated defensive gene expression. J Biol Chem 285, 153-162
DOI
|
35 |
Venugopal R and Jaiswal AK (1998) Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17, 3145-3156
DOI
|
36 |
Ernster L and Navazio F (1958) Soluble diaphorase in animal tissues. Acta Chem Scand 12, 595-602
DOI
|
37 |
Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-780
DOI
|
38 |
Chen H, Lum A, Seifried A et al (1999) Association of the NAD(P)H:quinone oxidoreducatase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 59, 3045-3048
|
39 |
Peng Q, Lu Y, Lao X et al (2014) The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis. Diagn Pathol doi:10.1186/1746-1596-9-100
DOI
|
40 |
Cornblatt BS, Ye L, Dinkova-Kostova AT et al (2007) Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis 28, 1485-1490
DOI
|
41 |
Lin P, Wang HJ, Lee H et al (1999) NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwna. J Toxicol Environ Health A 58, 187-197
DOI
|
42 |
Lewis SJ, Cherry NM, Niven RM et al (2001) Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 34, 177-183
DOI
|
43 |
Song SY, Jeong SY, Park HJ et al (2010) Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected nonsmall cell lung cancer. Lung Cancer 68, 278-282
DOI
|
44 |
Hamajima N, Matsuo K, Iwata H et al (2002) NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7, 103-108
|
45 |
Menzel HJ, Sarmanova J, Soucek P et al (2004) Association of NQO1 polymorphsim with spontaneous breast cancer in two independent populations. Br J Cancer 90, 1989-1994
DOI
|
46 |
Lajin B and Alachkar A (2013) The NQO1 polymorphsim C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis. Br J Cancer 109, 1325-1337
DOI
|
47 |
Zheng B, Wang Z and Chai R (2014) NQO1 C609T polymorphism and colorectal cancer susceptibility: a metaanalysis. Arch Med Sci 10, 651-660
DOI
|
48 |
Anwar A, Siegel D, Kepa JK et al (2002) Interaction of the molecular chaperone Hsp70 with human NAD(P)H: quinone oxidoreductase 1. J Biol Chem 277, 14060-14067
DOI
|
49 |
Fan Y, Hu D, Feng B and Wang W (2014) The NQO1 C609T polymorphism and hepatocellular carcinoma risk. Tumour Biol 35, 7343-7350
DOI
|
50 |
Cho CG, Lee SK, Nam SY et al (2006) Association of the GSTP1 and NQO1 polymorphsms and head and neck squamous cell carcinoma risk. J Korean Med Sci 21, 1075-1079
DOI
|
51 |
Traver RD, Horikoshi T, Danenberg KD et al (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52, 797-802
|
52 |
Ma Y, Kong J, Yan G et al (2014) NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer 14, 414. doi:10.1186/1471-2407-14-414
DOI
|
53 |
Yang Y, Zhang Y, Wu Q et al (2014) Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res 33,14. doi: 10.1186/1756-9966-33-14
DOI
|
54 |
Cresteil T and Jaiswal AK (1991) High levels of expression of the NAD(P)H: quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42, 1021-1027
DOI
|
55 |
Siegel D, Franklin WA and Ross D (1998) Immunohistochemical detection of NAD(P)H: quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4, 2065-2070
|
56 |
Winski SL, Koutalos Y, Bentley DL et al (2002) Subcellular localization of NAD(P)H:quinone oxidoreducatase 1 in human cancer cells. Cancer Res 62, 1420-1424
|
57 |
Ross D, Kepa JK, Winski SL et al (2000) NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 129, 77-97
DOI
|
58 |
Beall HD, Murphy AM, Siegel D et al (1995) Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48, 499-504
|
59 |
Siegel D, Gustafson DL, Dehn DL et al (2004) NAD(P)H: quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 65, 1238-1247
DOI
|
60 |
Gibson NW, Hartley JA, Butler J et al (1992) Relationship between DT-diaphorase mediated metabolism of a series of aziridinyl benzoquinones and DNA damage and cytotoxicity. Mol Pharmacol 42, 531-536
|
61 |
Gustafson DL, Beall HD, Bolton EM et al (1996) Expression of human NQO1 (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol 50, 728-735
|
62 |
Mikami K, Naito M, Tomida A et al (1996) DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 56, 2823-2826
|
63 |
Ross D, Beall HD, Siegel D et al (1996) Enzymology of bioreductive drug activation. Br J Cancer 74 (suppl. XXVII), S1-S8
DOI
|
64 |
Kelland LR, Sharp SY, Rogers PM et al (1999) DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91, 1940-1949
DOI
|
65 |
Goetz MP, Toft D, Reid J et al (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23, 1078-1087
DOI
|
66 |
Choi EK, Terai K, Ji IM et al (2007) Upregulation of NAD(P)H:Quinone Oxidoreductase by radiation potentiates the effect of bioreductive β -lapachone on cancer cells. Neoplasia 9, 634-642
DOI
|
67 |
Winski SL, Swann E, Hargreaves RH et al (2001) Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 61, 1509-1516
DOI
|
68 |
Loadman PM, Bibby MC, and Phillips RM (2002) Pharmacological approach towards the development of indole quinone bioreductive drugs used on the clinically inactive agent EO9. Br J Pharmacol 137, 701-709
DOI
|
69 |
Park HJ, Ahn KJ, Ahn SD et al (2005) Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation. Int J Radiat Oncol Biol Phys 61, 212-219
DOI
|
70 |
Suzuki M, Amano M, Choi J et al (2006) Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res 165, 525-531
DOI
|
71 |
Park HJ, Choi EK, Choi J et al (2005) Heat-induced up-regulation of NAD(P)H: quinone oxidoreductase potentiates anticancer effects of beta-lapachone. Clin Cancer Res 11, 8866-8871
DOI
|
72 |
Song CW, Chae JJ, Choi EK et al (2008) Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock. Int J Hyperthermia 24, 161-169
DOI
|
73 |
Dinkova-Kostova A and Talalay P (2010) NAD(P)H:quinone acceptor oxidoreducatase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 501, 116-123
DOI
|
74 |
Anwar A, Dehn D, Siegel D et al (2003) Interaction of human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 278, 10368-10373
DOI
|
75 |
Garate M, Wong RPC, Campos EI et al (2008) NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33ING1b. EMBO Rep 9, 576-581
DOI
|
76 |
Asher G, Tsvetkov P, Kahana C et al (2005) A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19, 316- 321
DOI
|
77 |
Asher G, Lotem J, Kama R et al (2001) NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A 99, 3099-3104
DOI
|
78 |
Patrick BA and Jaiswal AK (2012) Stress-induced NQO1 controls stability of C/EBP against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer. Oncogene 31, 4362-4371
DOI
|
79 |
Cuendet M, Oteham CP, Moon RC et al (2006) Quinone reductase induction as a biomarker for cancer chemoprevention. J Nat Prod 69, 460-463
DOI
|
80 |
Zhu H and Li Y (2012) NAD(P)H:quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovasc Toxicol 12, 39-45
DOI
|
81 |
Williams JB, Lu AYH, Cameron RG et al (1986) Rat liver NAD(P)H:quinone reductase. J Biol Chem 261, 5524-5528
|
82 |
Jaiswal AK, McBride OW, Adensik M et al (1988) Human dioxin-inducible cytosolic NAD(P)H:quinone oxidoreductase. J Biol Chem 263, 13572-13578
|
83 |
Nebert DW, Roe AL, Vandale SE et al (2002) NAD(P)H: quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 4, 62-70
DOI
|
84 |
Ross D, Kepa JK, Winski SL et al (2000) NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 129, 77-97
DOI
|
85 |
Wefers H and Sies H (1983) Hepatic low-level chemiluminescence during redox cycling of menadione and the menadione-glutathion conjugate: relation to glutathione and NAD(P)H:quinone reductase (DT-diaphorase) activity. Arch Biochem Biophys 224, 568-578
DOI
|
86 |
Atia A, Alrawaiq N and Abdullah A (2014) A review of NAD(P)H:quinone oxidoreductase 1 (NQO1); A multifunctional antioxidant enzyme. J Appl Pharm Sci 4, 118-122
|
87 |
Lind C, Cadenas E, Hochstein P et al (1990) DT-diaphorase: purification properties and function. Methods Enzymol 186, 287-301
DOI
|
88 |
Li R, Bianchet MA, Talalay P and Amzel LM (1995) The three dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two electron reduction. Proc Natl Acad Sci U S A 92, 8846-8850
DOI
|
89 |
Talalay P, and Dinkova-Kostova AT (2004) Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Meth Enzymol 382, 355-364
DOI
|
90 |
Cenas N, Anusevicius Z, Nivinskas H et al (2004) Structure-activity relationships in two-electron reduction of quinones. Meth Enzymol 382, 258-277
DOI
|
91 |
Ross D (2004) Quinone reductases multitasking in the metabolic world. Drug Metabol Rev 36, 639-654
DOI
|